Institutional shares held 567 Million
25.2M calls
5.08M puts
Total value of holdings $10.5B
$464M calls
$93.7M puts
Market Cap $20.5B
1,110,560,000 Shares Out.
Institutional ownership 51.09%
# of Institutions 611


Latest Institutional Activity in TEVA

Top Purchases

Q3 2024
National Pension Service Shares Held: 3.17M ($58.4M)
Q3 2024
Assenagon Asset Management S.A. Shares Held: 1.39M ($25.6M)
Q3 2024
Artemis Investment Management LLP Shares Held: 543K ($10M)
Q3 2024
Greenwood Capital Associates LLC Shares Held: 237K ($4.36M)
Q3 2024
Van Eck Associates Corp Shares Held: 1.88M ($34.6M)

Top Sells

Q3 2024
Australian Super Pty LTD Shares Held: 7.89M ($145M)
Q3 2024
Vontobel Holding Ltd. Shares Held: 628K ($11.6M)
Q3 2024
Private Management Group Inc Shares Held: 1.27M ($23.5M)
Q3 2024
Abrdn PLC Shares Held: 593K ($10.9M)
Q3 2024
Imc Chicago, LLC Shares Held: 33.3K ($614K)

About TEVA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.


Insider Transactions at TEVA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.28M Shares
From 20 Insiders
Exercise of conversion of derivative security 1.28M shares
Sell / Disposition
1.41M Shares
From 10 Insiders
Open market or private sale 1.41M shares

Track Institutional and Insider Activities on TEVA

Follow TEVA PHARMACEUTICAL INDUSTRIES LTD and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TEVA shares.

Notify only if

Insider Trading

Get notified when an Teva Pharmaceutical Industries LTD insider buys or sells TEVA shares.

Notify only if

News

Receive news related to TEVA PHARMACEUTICAL INDUSTRIES LTD

Track Activities on TEVA